Biomarkers That Predict Eczema Treatment Response: A Systematic Review

November 9, 2026

AI-generated illustration: Dr. Arsy jar beside a skincare journal

Evidence summary for education only; not individualized medical advice.

Why prediction matters

People with eczema may cycle through therapies before finding an effective, tolerable option. A systematic review assessed biomarkers proposed to forecast response or adverse outcomes.

Candidate does not mean clinically ready

Many markers appear promising in small cohorts or post-hoc analyses. Results can be unstable when assays differ, thresholds are chosen after seeing the data or the same participants are used for discovery and testing.

What a useful biomarker must show

It should add value beyond age, severity, comorbidity and prior treatment; reproduce in independent cohorts; and change a decision in a way that improves outcomes. Statistical association alone is insufficient.

Drug-specific evidence

A marker associated with one biologic or JAK inhibitor cannot be generalized to every therapy. Comparative prediction requires studies designed to separate prognosis from treatment interaction.

Safety

No experimental test should be used to start, stop or switch prescription eczema therapy without qualified clinical interpretation. Pediatric use requires age-specific evidence.

Bottom line

Precision dermatology is advancing, but most proposed eczema biomarkers remain research tools rather than validated standalone decision tests.

Related Dr. Arsy research

References

← Back to Doctor's Notes